Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors

被引：28
|
作者：
Mitmaker, Elliot J. [1 ]
Griff, Nicholas J. [1 ]
Grogan, Raymon H. [1 ]
Sarkar, Rajabrata [2 ]
Kebebew, Electron [3 ]
Duh, Quan-Yang [1 ]
Clark, Orlo H. [1 ]
Shen, Wen T. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[2] Univ Maryland, Dept Surg, Baltimore, MD 21201 USA
[3] NCI, Endocrine Surg Sect, Surg Branch, Bethesda, MD 20892 USA
来源：
SURGERY | 2011年 / 149卷 / 04期
关键词：
NA+/I-SYMPORTER; GROWTH-FACTOR; PROTEIN EXPRESSION; TISSUE INHIBITORS; MESSENGER-RNA; CYCLE ARREST; LUNG-CANCER; METASTASIS; CARCINOMA; APOPTOSIS;
D O I：
10.1016/j.surg.2010.10.007
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Background. The purpose of this study was to investigate the effects. of treating human. thyroid cancer cell lines with demethylating agents and histone deacetylase (HDAC) inhibitors to see if they would downregulate expression and activity of the matrix metalloproteinases (MMP)-2 and MMP-9, resulting in inhibition of growth and invasion. Methods. A total of I papillary cancer cell line (TPC-I) and 3 follicular thyroid cancer cell lines (FTC-133, FIC-236, and FTC-238) were treated with the demethylating agent 5-azacylidine (5-AZC) and the HDAC inhibitors trichostatin A (TSA) and valproic acid (VA). The activity of MMP proteins was determined using gelatin zymography, and commercially available assays were used to quantify growth inhibition and thyroid cancer cell invasion. Results. Treatment with TSA and VA resulted in decreased protein activity of MMP-2 and MMP-9 in all cell lines in. a dose-dependent manner after 48 hours of treatment compared with untreated controls. In. addition, 5-, TSA, and VA caused inhibition of growth in the range of 25-80% for all cell lines at 24,48 and 72 hours VA and TSA significantly decreased cell invasion in the FTC-133 and TPC-I cell lines. Conclusion. The HDAC inhibitors TSA and VA decreased the protein activity of MMP-2 and MMP-9 and, in combination with the demethylating agent 5-AZC inhibited cellular growth in human papillary and follicular thyroid cancer cell lines. These results elucidate our understanding of the pathways affected by the demethylating agents and HDAC inhibitors, and provide further evidence that MMPs are a potentially useful target for molecular therapies in patients with aggressive or refractory thyroid cancers. (Surgery 2011;149:504-11).
引用
收藏
页码：504 / 511
页数：8
相关论文
共 50 条
  • [1] Radiosensitization by histone deacetylase inhibitors +/- demethylating agents in head and neck cancer cell lines
    De Schuller, H.
    Van Criekinge, W.
    Nuyts, S.
    [J]. EJC SUPPLEMENTS, 2007, 5 (08): : 23 - 23
  • [2] Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy
    Piekarz, Richard L.
    Sackett, Dan L.
    Bates, Susan E.
    [J]. CANCER JOURNAL, 2007, 13 (01): : 30 - 39
  • [3] Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines
    Emionite, L
    Galmozzi, F
    Grattarola, M
    Boccardo, F
    Vergani, L
    Toma, S
    [J]. ANTICANCER RESEARCH, 2004, 24 (06) : 4019 - 4024
  • [4] Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
    Sakajiri, S
    Kumagai, T
    Kawamata, N
    Saitoh, T
    Said, JW
    Koeffler, HP
    [J]. EXPERIMENTAL HEMATOLOGY, 2005, 33 (01) : 53 - 61
  • [5] Insights on histone deacetylase inhibitors - induced cell death in cancer cell lines
    Saceda, M.
    Castroviejo, N.
    Gomez-Martinez, A.
    Martinez-Lacaci, I.
    Caruana, P.
    Ventero, M.
    Garcia-Morales, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S41 - S42
  • [6] Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines
    Owonikoko, Taofeek K.
    Zhang, Guojing
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    Sun, Shi-Yong
    [J]. CANCER RESEARCH, 2010, 70
  • [7] Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines
    Kiliccioglu, I.
    Konac, E.
    Varol, N.
    Gurocak, S.
    Bilen, C. Yucel
    [J]. GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02) : 3721 - 3731
  • [8] Insights into histone deacetylase inhibitors-induced apoptosis in cancer cell lines
    Ruiz-Rico, P.
    Menendez-Gutierrez, M. P.
    Carrasco-Garcia, E.
    Martinez-Mira, R.
    Rocamora-Reverte, L.
    Jimenez-Pulido, I.
    Martinez-Lacaci, I.
    Garcia-Morales, M. P.
    Ferragut, J. A.
    Saceda, M.
    [J]. EJC SUPPLEMENTS, 2008, 6 (09): : 28 - 28
  • [9] Histone Deacetylase Inhibitory Activity of Peanut Testa Extracts against Human Cancer Cell Lines
    Khaopha, Somprasong
    Jogloy, Sanun
    Patanothai, Aran
    Senawong, Thanaset
    [J]. JOURNAL OF FOOD BIOCHEMISTRY, 2015, 39 (03) : 263 - 273
  • [10] Histone Deacetylase Inhibitors As Enhancers of Human Hematopoietic Stem Cell Activity
    Wobus, Manja
    Arulmozhivarman, Guruchandar
    Kraeter, Martin
    Friedrichs, Jens
    Stoeter, Martin
    Bornhaeuser, Martin
    [J]. BLOOD, 2016, 128 (22)
12345